Clinical Trial Update: NPI-002 Intravitreal Implant for the Delay of Cataract Progression [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates that Nacuity Pharmaceuticals' NPI-002 intravitreal implant is being studied in Phase 1/2 trials to delay cataract progressi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• NPI-002 Intravitreal Implant (NPI-002 intravitreal implant)

Snippet

Sponsor: Nacuity Pharmaceuticals, Inc. | Conditions: Cataract | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING